1. Abrams AJ, Wang TC. Adenocarcinoma and other tumors of the stomach. In: Feldman M, Friedman LS, Brandt LJ (eds): Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. Pathophysiology/Diagnosis/Management. 9th ed. Philadelphia: WB Saunders, 2010.
2. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69–90.
3. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12 (3): 354–62.
4. Parkin DM. International variation. Oncogene 2004; 23: 6329–40.
5. Parkin DM, Whelan SL, Ferlay J. Cancer Incidence in Five Continents, vol VII. Lyon, France: International Agency for Research on Cancer, 1997: 822–3.
6. Nomura A. Stomach Cancer. In: Schottenfeld D, Fraumeni JF, eds. Cancer Epidemiology and Prevention. 2nd ed. New York: Oxford University Press, 1996: 707–24.
7. Parsonnet J. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9 (Suppl. 2): 45–51.
8. Pandey R, Misra V, Misra SP et al. Helicobacter pylori and gastric cancer. Asian Pac J Cancer Prev 2010; 11 (3): 583–8.
9. Correa P. Helicobacter pylori and gastric cancer: state of the art. Cancer Epidemiol Biomarkers Prev 1996; 5: 477–81.
10. Barreto-Zuniga R, Maruyama M, Kato Y et al. Significance of Helicobacter pylori infection as a risk factor in gastric cancer: serological and histological studies. J Gastroenterol 1997; 32: 289–94.
11. Miehlke S, Hackelsberger A, Meining A et al. Histological diagnosis of Helicobacter pylori gastritis is predictive of a high risk of gastric carcinoma. Int J Cancer 1997; 73: 837–9.
12. Nomura AM, Stemmermann GN, Chyou PH. Gastric cancer among the Japanese in Hawaii. Jpn J Cancer Res 1995; 86: 916–23.
13. Forman D, Newell DG, Fullerton F et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ 1991; 302: 1302–5.
14. Kamangar F, Qiao YL, Blaser MJ et al. Helicobacter pylori and oesophageal and gastric cancers in a prospective study in China. Br J Cancer 2007; 96:172–6.
15. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784–9.
16. Аруин Л.И. Из 100 инфицированных Helicobacter pylori РЖ возникает у двоих. Кто они? Эксперим. и клин. гастроэнтерология. 2004; 1: 12–8.
17. Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997; 40: 297–301.
18. Hatakeyama M. Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis. Cell Host Microbe 2014; 15 (3): 306–16.
19. Vicari JJ, Peek RM, Falk GW et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998; 115: 50–7.
20. Azuma T, Yamakawa A, Yamazaki S et al. Correlation between variation of the 3’ region of the CagA gene in Helicobacter pylori and disease outcome in Japan. J Infect Dis 2002; 186: 1621–30.
21. Wroblewski LE, Peek RM Jr. Helicobacter pylori in gastric carcinogenesis mechanisms. Gastroenterol Clin N Am 2013; 42: 285–98.
22. Mowat C, Carswell A, Wirz A, McColl KE. Omeprazole and dietary nitrate independently affect levels of vitamin C and nitrite in gastric juice. Gastroenterology 1999; 116:813–22.
23. Oldreive C, Rice-Evans C. The mechanisms for nitration and nitrotyrosine formation in vitro and in vivo: Impact of diet. Free Radic Res 2001; 35: 215–31.
24. Sugimura T, Fujimura S, Baba T. Tumor production in the glandular stomach and alimentary tract of the rat by N-methyl-N′-nitro-N-nitrosoguanidine. Cancer Res 1970; 30: 455–65.
25. Bartsch H, Ohshima H, Pignatelli B, Calmels S. Human exposure to endogenous N-nitroso compounds: Quantitative estimates in subjects at high risk for cancer of the oral cavity, oesophagus, stomach and urinary bladder. Cancer Surv 1989; 8: 335–62.
26. Knekt P, Jarvinen R, Dich J, Hakulinen T. Risk of colorectal and other gastro-intestinal cancers after exposure to nitrate, nitrite and N-nitroso compounds: A follow-up study. Int J Cancer 1999; 80: 852–6.
27. Jakszyn P, Bingham S, Pera G et al. Endogenous versus exogenous exposure to N-nitroso compounds and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study. Carcinogenesis 2006; 27:1497–501.
28. Van Loon AJ, Botterweck AA, Goldbohm RA et al. Intake of nitrate and nitrite and the risk of gastric cancer: A prospective cohort study. Br J Cancer 1998; 78:129–35.
29. Fox JG, Dangler CA, Taylor NS et al. High-salt diet induces gastric epithelial hyperplasia and parietal cell loss, and enhances Helicobacter pylori colonization in C57BL/6 mice. Cancer Res 1999; 59: 4823–8.
30. Correa P, Haenszel W, Cuello C et al. Gastric precancerous process in a high risk population: Cohort follow-up. Cancer Res 1990; 50: 4737–40.
31. Ramon JM, Serra L, Cerdo C, Oromi J. Dietary factors and gastric cancer risk. A case-control study in Spain. Cancer 1993; 71: 1731–5.
32. Nazario CM, Szklo M, Diamond E et al. Salt and gastric cancer: A case-control study in Puerto Rico. Int J Epidemiol 1993; 22: 790–7.
33. Gonzalez CA, Jakszyn P, Pera G et al. Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2006; 98: 345–54.
34. Gonzalez CA, Pera G, Agudo A et al. Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Int J Cancer 2006; 118: 2559–66.
35. Loh JT, Torres VJ, Cover TL. Regulation of Helicobacter pylori cagA expression in response to salt. Cancer Res 2007; 67: 4709–15.
36. Gamboa-Dominguez A, Ubbelohde T, Saqui-Salces M et al. Salt and stress synergize H. pylori-induced gastric lesions, cell proliferation, and p21 expression in Mongolian gerbils. Dig Dis Sci 2007; 52:1517–26.
37. Kuper H, Boffetta P, Adami HO. Tobacco use and cancer causation: Association by tumour type. J Intern Med 2002; 252: 206–24.
38. Gonzalez CA, Pera G, Agudo A, et al. Smoking and the risk of gastric cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). Int J Cancer 2003; 107: 629–34.
39. Sung NY, Choi KS, Park EC et al. Smoking, alcohol and gastric cancer risk in Korean men: The National Health Insurance Corporation Study. Br J Cancer 2007; 97: 700–4.
40. Sjodahl K, Lu Y, Nilsen TI et al. Smoking and alcohol drinking in relation to risk of gastric cancer: A population-based, prospective cohort study. Int J Cancer 2007; 120: 128–32.
41. Ladeiras-Lopes R, Pereira AK, Nogueira A et al. Smoking and gastric cancer: Systematic review and meta-analysis of cohort studies. Cancer Causes Control 2008; 19: 689–701.
42. Freedman ND, Abnet CC, Leitzmann MF et al. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol 2007; 165: 1424–33.
43. Larsson SC, Bergkvist L, Naslund I et al. Vitamin A, retinol, and carotenoids and the risk of gastric cancer: A prospective cohort study. Am J Clin Nutr 2007; 85: 497–503.
44. Larsson SC, Giovannucci E, Wolk A. Alcoholic beverage consumption and gastric cancer risk: a prospective population-based study in women. Int J Cancer 2007; 120: 373–7.
45. Gammon MD, Schoenberg JB, Ahsan H et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1997; 89: 1277–84.
46. Renehan AG, Tyson M, Egger M et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569–78.
47. Abnet CC, Freedman ND, Hollenbeck AR et al. A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. Eur J Cancer 2008; 44: 465–71.
48. Merry AH, Schouten LJ, Goldbohm RA, van den Brandt PA. Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: A prospective cohort study. Gut 2007; 56: 1503–11.
49. MacInnis RJ, English DR, Hopper JL, Giles GG. Body size and composition and the risk of gastric and oesophageal adenocarcinoma. Int J Cancer 2006; 118: 2628–31.
50. Chow WH, Blot WJ, Vaughan TL et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998; 90:150–5.
51. Lindblad M, Rodriguez LA, Lagergren J. Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. Cancer Causes Control 2005; 16: 285–94.
52. Zanghieri G, Di Gregorio C, Sacchetti C et al. Familial occurrence of gastric cancer in the 2-year experience of a population-based registry. Cancer 1990; 66: 2047–51.
53. Brenner H, Arndt V, Sturmer T et al. Individual and joint contribution of family history and Helicobacter pylori infection to the risk of gastric carcinoma. Cancer 2000; 88: 274–9.
54. Parsonnet J. When heredity is infectious. Gastroenterology 2000; 118: 222–4.
55. Leung WK, Ng EK, Chan WY et al. Risk factors associated with the development of intestinal metaplasia in first-degree relatives of gastric cancer patients. Cancer Epidemiol Biomarkers Prev 2005; 14: 2982–6.
56. Zwick A, Munir M, Ryan CK et al. Gastric adenocarcinoma and dysplasia in fundic gland polyps of a patient with attenuated adenomatous polyposis coli. Gastroenterology 1997; 113: 659–63.
57. Bianchi LK, Burke CA, Bennett AE et al. Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2008; 6:180–5.
58. Aarnio M, Salovaara R, Aaltonen LA et al. Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. Int J Cancer 1997; 74: 551–5.
59. Coburn MC, Pricolo VE, DeLuca FG, Bland KI. Malignant potential in intestinal juvenile polyposis syndromes. Ann Surg Oncol 1995; 2: 386–91.
60. Howe JR, Mitros FA, Summers RW. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol 1998; 5: 751–6.
61. Tamura G, Yin J, Wang S et al. E-cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 2000; 92: 569–73.
62. Yoon KA, Ku JL, Yang HK et al. Germline mutations of E-cadherin gene in Korean familial gastric cancer patients. J Hum Genet 1999; 44: 177–80.
63. El-Omar EM, Carrington M, Chow WH et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404:398–402.
64. El-Omar EM, Rabkin CS, Gammon MD et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003; 124: 1193–201.
65. Cheng D, Hao Y, Zhou W, Ma Y. Positive association between Interleukin-8 -251A>T polymorphism and susceptibility to gastric carcinogenesis: a meta-analysis. Cancer Cell Int 2013; 13 (1): 100.
66. Wadhwa R, Song S, Lee JS et al. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol 2013; 10 (11): 643–55.
67. Shimizu N, Ikehara Y, Inada K et al. Eradication diminishes enhancing effects of Helicobacter pylori infection on glandular stomach carcinogenesis in Mongolian gerbils. Cancer Res 2000; 60: 1512–4.
68. Nozaki K, Shimizu N, Ikehara Y et al. Effect of early eradication on Helicobacter pylori-related gastric carcinogenesis in Mongolian gerbils. Cancer Sci 2003; 94: 235–9.
69. Cai X, Carlson J, Stoicov C et al. Helicobacter felis eradication restores normal architecture and inhibits gastric cancer progression in C57BL/6 mice. Gastroenterology 2005; 128: 1937–52.
70. You WC, Brown LM, Zhang L et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006; 98: 974–83.
71. Take S, Mizuno M, Ishiki K et al. The effect of eradicating helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol 2005; 100: 1037e42.
72. Fuccio L, Zagari RM, Eusebi LH et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009; 151: 121e8.
73. De Vries AC, Kuipers EJ. Review article: helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther 2007; 26(Suppl. 2): 25e35.
74. De Vries AC, Kuipers EJ. Epidemiology of premalignant gastric lesions: implications for the development of screening and surveillance strategies. Helicobacter 2007; 12 (Suppl. 2): 22–31.
75. Wang J, Xu L, Shi R et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion 2011; 83: 253e60.
76. Rokkas T, Pistiolas D, Sechopoulos P et al. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter 2007; 12 (Suppl. 2): 32e8.
77. Howe LR, Dannenberg AJ. A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer. Semin Oncol 2002; 29 
(3 Suppl. 11):111–9.
78. Saukkonen K, Rintahaka J, Sivula A et al. Cyclooxygenase-2 and gastric carcinogenesis. Apmis 2003; 111: 915–25.
79. Wang WH, Huang JQ, Zheng GF et al. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2003; 95 (23): 1784–91.
80. Yang P, Zhou Y, Chen B et al. Aspirin use and the risk of gastric cancer: a meta-analysis. Dig Dis Sci 2010; 55 (6): 1533–9.
81. Kobayashi M, Tsubono Y, Sasazuki S et al. Vegetables, fruit and risk of gastric cancer in Japan: A 10-year follow-up of the JPHC Study Cohort I. Int J Cancer 2002; 102: 39–44.
82. Larsson SC, Bergkvist L, Wolk A. Fruit and vegetable consumption and incidence of gastric cancer: A prospective study. Cancer Epidemiol Biomarkers Prev 2006; 15: 1998–2001.
83. Freedman ND, Subar AF, Hollenbeck AR et al. Fruit and vegetable intake and gastric cancer risk in a large United States prospective cohort study. Cancer Causes Control 2008; 19: 459–67.
84. Zhang Z, Xu G, Ma M et al. Dietary fiber intake reduces risk for gastric cancer: a meta-analysis. Gastroenterology 2013; 145: 113.
85. Plummer M, Vivas J, Lopez G et al. Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation: A randomized trial in a high-risk population. J Natl Cancer Inst 2007; 99: 137–46.
86. Masuda M, Suzui M, Lim JT, Weinstein IB. Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin Cancer Res 2003; 9: 3486–91.
87. Henning SM, Wang P, Carpenter CL, Heber D. Epigenetic effects of green tea polyphenols in cancer. Epigenomics 2013; 5 (6): 729–41.
88. Hou IC, Amarnani S, Chong MT, Bishayee A. Green tea and the risk of gastric cancer: epidemiological evidence. World J Gastroenterol 2013; 19 (24): 3713–22.

И.В.Маев, Д.Н.Андреев

ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России

________________________________________________

I.V.Maev, D.N.Andreev